Abstract

After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies.

However, translating this information into disease insights and ultimately into tractable therapeutic targets is a major challenge.

Here we consider how different sources of information might be integrated to guide this process.

We review how an understanding of neurobiology has been used to advance therapeutic candidates identified in the pre-genomic era, using catechol-O-methyltransferase (COMT) as an exemplar.

We then contrast with ZNF804A, the first genome-wide significant schizophrenia gene, and draw on some of the lessons that these and other examples provide.

We highlight that, at least in the short term, the translation of potential targets for which there is orthogonal neurobiological support is likely to be more straightforward and productive than that those relying solely on genomic information.

Although we focus here on information from genomic studies of schizophrenia, the points are broadly applicable across major psychiatric disorders and their symptoms.

Citations

Paul J. Harrison, Arne Mould, Elizabeth M. Tunbridge, New drug targets in psychiatry: Neurobiological considerations in the genomics era, Neuroscience & Biobehavioral Reviews, Volume 139, 2022, 104763,

DOI: https://doi.org/10.1016/j.neubiorev.2022.104763

URI: https://www.oxfordhealth.nhs.uk/orka/title/new-drug-targets-in-psychiatry-neurobiological-considerations-in-the-genomics-era/